ATAI Launches Subsidiary Focused on DMT
Psychedelics and biotech company ATAI Life Sciences announced the launch of Viridia Life Sciences, a wholly-owned subsidiary that will be dedicated to the study and production of the DMT molecule (N,N-Dimethyltryptamine).
DMT is the active ingredient in ayahuasca, a hallucinogenic brew traditionally used in spiritual practices by indigenous communities of the Amazon basin.
ATAI said that Viridia is leveraging the platform’s own drug development experience to formulate DMT products based on alternative routes of administration.
“Viridia’s DMT products will be developed with the specific aim of controlling the rate of which the drug is released and absorbed, which has a direct impact on …